LONDON, May 1, 2026, 18:08 (BST)
Halma jumped 120p, gaining 2.72% to finish at 4,527p on Friday. That move put the safety and health tech group close to its all-time highs, easily beating a lackluster FTSE 100, which slipped 0.14%.
This puts Halma roughly 1.2% below its record high of 4,580p from April 17, and its full-year numbers are expected June 11. Eyes are on whether the group can back up its 2026 guidance boost with a solid earnings release.
No new regulatory statement from Halma triggered the rally. The most recent RNS from the company, which is the London market’s official announcement channel, was an April 13 acquisition disclosure. Before that, Halma posted a March 12 trading update.
Back in March, Halma reaffirmed its outlook, sticking with its forecast for organic constant currency revenue growth in the mid-teens for the year ending March 31. That metric leaves out both acquisition impacts and currency fluctuations. The group also pointed to an adjusted EBIT margin near 22%. Adjusted EBIT excludes specific one-off and acquisition-related charges.
M&A is still in the spotlight. On April 13, Halma announced the $90 million acquisition of Surgistar, a California company specializing in ophthalmic surgical tools and devices. The deal—roughly £67 million—serves as a bolt-on for MicroSurgical Technology within Halma’s Healthcare division.
Chief Executive Marc Ronchetti pointed to steady demand in the eye-care space, calling “cataract and ophthalmic surgery…long term growth markets for Halma.” Surgistar, the company said, brings products for standard cataract procedures and bolsters Halma’s own manufacturing arm. Halma
March’s update landed more as confirmation than anything new, analysts noted. Lauren Baker at Peel Hunt called it evidence of “strong progress in the second half.” UBS—still bullish with its buy rating and a 4,200p target—turned focus to 2027 guidance, particularly the growth outlook for photonics, that’s light-based tech for sensing and analysis. Proactiveinvestors UK
UBS took a selective view last year, lumping Halma in with Renishaw and Spirax as top picks among UK engineers. The bank called out earnings growth as the key driver—sector-wide recovery wasn’t going to cut it, in their view.
The hurdle’s steeper this time. Back in March, Halma cautioned that a stronger sterling could shave roughly £63 million off reported revenue and trim profit by about £14 million for 2026, both numbers measured against 2025. The company also flagged uneven end-market trends and a murky economic and geopolitical outlook.
Bulls will take note of the latest results. Halma’s first-half revenue climbed 15.2% to £1.24 billion, with adjusted pre-tax profit jumping 29.3% to £270.5 million. The interim dividend is going up as well—now 9.63p a share, a 7% increase.
Halma’s reach spans Safety, Environment, and Health, with products ranging from fire safety equipment to environmental monitoring tools, water analysis systems, and healthcare technology. According to FT market data, revenue for the trailing 12 months landed at £2.25 billion, with a headcount near 9,290.
Next up: results on June 11. If the order book holds firm and margins look solid, the almost-high watermark for the share price might stand. But a hint of weakness around photonics, cash conversion, or how well acquisitions are paying off could put Friday’s rally on shaky ground.
